Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Get Free Report) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 34,200 shares, a growth of 9.6% from the September 15th total of 31,200 shares. Currently, 2.3% of the company’s shares are sold short. Based on an average daily trading volume, of 2,560,000 shares, the days-to-cover ratio is presently 0.0 days.
Wall Street Analysts Forecast Growth
Separately, StockNews.com initiated coverage on Galmed Pharmaceuticals in a report on Wednesday, October 9th. They issued a “sell” rating on the stock.
Check Out Our Latest Analysis on Galmed Pharmaceuticals
Galmed Pharmaceuticals Price Performance
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last issued its earnings results on Wednesday, August 28th. The biopharmaceutical company reported $2.16 earnings per share (EPS) for the quarter.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Recommended Stories
- Five stocks we like better than Galmed Pharmaceuticals
- High Flyers: 3 Natural Gas Stocks for March 2022
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- 3 Stocks to Consider Buying in October
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.